Severe acute respiratory syndrome outbreak

Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

Retrieved on: 
Monday, August 14, 2023
Vaccine, Cocrystal, PK, Disease, Norovirus, Therapy, Medicine, SARS-CoV-2, COVID-19, API, Enzyme, Health, SARS, Pharmacokinetics, World Health Organization, G&A, Research, Influenza, RNA, CDC, Gastroenteritis, Death, OPKO Health, MERS, Korea Disease Control and Prevention Agency, Protease, Warburg Pincus, Viral, CFO, Medicines and Healthcare products Regulatory Agency, Merck, Severe acute respiratory syndrome outbreak, Liver, FDA, R, Safety, IND, HCV, COCP, Pharmaceutical industry, Cryptocurrency, Medical device, Management, Video game

Our drug discovery process focuses on the highly conserved regions of the viral enzymes and inhibitor-enzyme interactions at the atomic level.

Key Points: 
  • Our drug discovery process focuses on the highly conserved regions of the viral enzymes and inhibitor-enzyme interactions at the atomic level.
  • Research and development (R&D) expenses for the second quarter of 2023 were $2.8 million, compared with $2.4 million for the second quarter of 2022.
  • Cocrystal reported unrestricted cash as of June 30, 2023 of $32.4 million, compared with $37.1 million as of December 31, 2022.
  • During the second quarter of 2023, the Company raised $4.0 million in a private placement offering of common stock that was priced “at-the-market” under Nasdaq Listing Rules.

Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Friday, August 4, 2023
Patent, Intellectual property, Inhalation, Australian patent law, Pathogenic bacteria, Conditioned place preference, Cytomegalovirus, HIV, EBV, SARS-CoV-2, Streptococcus pyogenes, Coronavirus, COVID-19, Recce, Gonorrhea, Skin, ASX, FSE, Burn, Staphylococcus, Shingles, Escherichia coli, Severe acute respiratory syndrome outbreak, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Simplex, PCT, Viral disease, Urinary tract infection, Pseudomonas aeruginosa, Administration, Neisseria meningitidis, Biology, Ross River virus, Viral, Infection, Bacteria, Family, Virus, HCMV, Disease, RCE, Pharmaceutical industry, Vaccine, Proteus, Serratia, Enterococcus

SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We are thrilled to receive this new family of intellectual property, granted by the Australian Patent Office, with further market monopolies reinforcing opportunities among a significant range of bacterial and viral pathogens,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Viral infections may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), including herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include Influenza A, Ross River virus, and coronavirus, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

COVID: how incorrect assumptions and poor foresight hampered the UK's pandemic preparedness

Retrieved on: 
Friday, June 30, 2023
Cygnus, Vaccine, Exercise, Disease, Travel, Personal protective equipment, SARS-CoV-2, Coronavirus, COVID-19, SARS, Immunity, Exercise Cygnus, COVID, Government, Thought, Quarantine, Death, PPE, Population, Time, Risk, Mortality, Severe acute respiratory syndrome outbreak, Health, Tutoring

Matt Hancock, the former health secretary, has told the recently opened COVID-19 Inquiry that the UK’s pandemic planning was “completely wrong”.

Key Points: 
  • Matt Hancock, the former health secretary, has told the recently opened COVID-19 Inquiry that the UK’s pandemic planning was “completely wrong”.
  • While there is truth in this claim, it doesn’t give us the whole picture.
  • In 2016, the UK government engaged in a series of exercises including Cygnus to assess their preparedness and response to a pandemic outbreak of influenza.
  • Without effective vaccines, any attempt at herd immunity had to be abandoned as too many people would have died in the meantime.

Flawed assumptions

    • Countries that had been significantly affected by the Severe Acute Respiratory Syndrome (SARS) outbreak in 2002–2004 – principally China but also other Asian countries – didn’t make the same mistake.
    • In contrast, the UK lost valuable time between mid-February and mid-March while COVID cases and subsequent deaths were rapidly beginning to rise.

Poor planning

    • Hancock’s statement raises a key question about the extent to which errors in the UK’s pandemic planning could have been foreseen at the time.
    • Notably, the UK’s healthcare planning authorities could have taken a wider view of the potential nature of viral pandemics.
    • Nevertheless, it wouldn’t have been unreasonable to include the global re-emergence of a SARS-type virus as one of the possible, albeit more extreme, pandemic scenarios analysed in the UK’s planning exercises in 2016.
    • Read more:
      How to prepare for a pandemic

      In sum, no planning exercise can cover all eventualities.

Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

Retrieved on: 
Monday, May 15, 2023
Cocrystal, Insurance, Enzyme, SARS, Warburg Pincus, Gastroenteritis, District court, Coronavirus diseases, Investment, Protease, Merck, Medicines and Healthcare products Regulatory Agency, Severe acute respiratory syndrome outbreak, Human, Influenza A virus, Pharmacokinetics, Research, United States Court of Appeals for the Third Circuit, MERS, United States Court of Appeals for the Armed Forces, Comment, Liver, Security (finance), FDA, IND, Safety, Disease, COVID-19, Health, Influenza, Judgement, OPKO Health, Form, Viral, CFO, PK, SARS-CoV-2, Clinical trial, RNA, Form S-3, Virginia General District Court, HCV, World Health Organization, COCP, Cryptocurrency, Pharmaceutical industry, Vaccine, Management, Norovirus

BOTHELL, Wash., May 15, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three months ended March 31, 2023 and provides updates on its antiviral pipeline, upcoming milestones and business activities.

Key Points: 
  • BOTHELL, Wash., May 15, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three months ended March 31, 2023 and provides updates on its antiviral pipeline, upcoming milestones and business activities.
  • “Recent progress in advancing our pipeline of antiviral drug candidates keeps us on pace to meet our 2023 milestones,” said Sam Lee, Ph.D., President and co-CEO of Cocrystal.
  • Research and development expenses for the first quarter of 2023 were $3.9 million, compared with $2.9 million for the first quarter of 2022.
  • General and administrative expenses for the first quarter of 2023 were $1.2 million, compared with $1.3 million for the first quarter of 2022.

Recce Pharmaceuticals to be Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Tuesday, April 11, 2023
Patent, Inhalation, Australian patent law, Veterans' Preference Act of 1944, Cytomegalovirus, HIV, EBV, SARS-CoV-2, Streptococcus pyogenes, Recce, Gonorrhea, Skin, ASX, FSE, Burn, Staphylococcus, Shingles, Escherichia coli, Severe acute respiratory syndrome outbreak, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Simplex, Varicella zoster virus, PCT, Viral disease, Urinary tract infection, Pseudomonas aeruginosa, Administration, Neisseria meningitidis, Patient, Biology, Ross River virus, Viral, Infection, Bacteria, Virus, HCMV, Disease, RCE, Pharmaceutical industry, Vaccine, Proteus, Serratia, Enterococcus

SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We would like to thank the Australian Patent Office for this notification of intent, which further validates the potential of our new class of anti-infectives to help patients with a broad range of bacterial and viral infections,” said James Graham, Chief Executive Officer of Recce Pharmaceutical.
  • Viral infections that may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), include herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome.

Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs

Retrieved on: 
Wednesday, March 29, 2023
Cocrystal, PK, Insurance, GLP, Gastroenteritis, Human, Disease, Omicron, Influenza, SARS-CoV-2, COVID-19, Influenza A virus, Enzyme, SARS, Pharmacokinetics, World Health Organization, Research, RNA, United States Court of Appeals for the Third Circuit, Judgement, MERS, Coronavirus diseases, Protease, Toxicology, Viral, CFO, Severe acute respiratory syndrome outbreak, Liver, Merck, Medicines and Healthcare products Regulatory Agency, United States Court of Appeals for the Armed Forces, FDA, IND, HCV, Safety, COCP, Cryptocurrency, Pharmaceutical industry, Vaccine, Sofosbuvir/velpatasvir, Norovirus

BOTHELL, Wash., March 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the 12 months ended December 31, 2022, and provides updates on its antiviral pipeline, upcoming milestones and business activities.

Key Points: 
  • BOTHELL, Wash., March 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the 12 months ended December 31, 2022, and provides updates on its antiviral pipeline, upcoming milestones and business activities.
  • “This is an eventful time for Cocrystal with multiple near-term milestones with our highly promising antiviral programs,” said Sam Lee, Ph.D., President and co-CEO of Cocrystal.
  • In December 2022 we reported favorable safety and tolerability results from the Phase 1 study with CC-42344 for influenza A.
  • Cocrystal reported unrestricted cash of $37.1 million as of December 31, 2022 compared with $58.7 million as of December 31, 2021.

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Retrieved on: 
Wednesday, February 15, 2023
Well, Patent, SARS, Collection, Gram, Infection, Tocilizumab, Acute respiratory distress syndrome, CAR, Immunotherapy, CAPS, De novo, HLH, LPS, Smallpox, Acute pancreatitis, Cancer, NLRP3, CINCA, MAS, Sepsis, Patient, Macrophage activation syndrome, Muckle–Wells syndrome, Inhalation, GPI, Therapy, FCAS, FDA, Hemophagocytic lymphohistiocytosis, Trauma, Severe acute respiratory syndrome outbreak, MWS, Cytokine release syndrome, Malaria, FCU, Vaccine

Nes-Ziona, Israel, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 284985, entitled, “Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment.” The patent provides added intellectual property protection in Israel into at least 2037, with claims covering the use of for Allocetra™ for prevention or amelioration of cytokine storms in cancer patients receiving CAR-T therapy, as well as in patients whose cytokine storms result from infectious diseases or non-infectious sources.

Key Points: 
  • Nes-Ziona, Israel, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 284985, entitled, “Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment.” The patent provides added intellectual property protection in Israel into at least 2037, with claims covering the use of for Allocetra™ for prevention or amelioration of cytokine storms in cancer patients receiving CAR-T therapy, as well as in patients whose cytokine storms result from infectious diseases or non-infectious sources.
  • CAR T-cells are T-cells that have been genetically modified to include a receptor that allows them to specifically target and destroy cancer cells.
  • While certain CAR T-cell treatments were recently approved by the FDA in several cancer indications, such treatments have been associated in many patients with a side effect named cytokine release syndrome, which describes a collection of potentially severe or life-threatening symptoms that stem from over-activation of immune pathways.
  • Preclinical data indicate that Allocetra™ has the potential to prevent or ameliorate cytokine release syndrome associated with CAR T-cell therapies.